Catalyst Wire Dossier Catalyst Wire Dossier

Xelevia

sitagliptin · Merck Sharp & Dohme B.V.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Xelevia, covering 2025-12-01 to 2025-12-01. Get the full timeline:

Most recent: EMA Authorised: Xelevia (sitagliptin) — Merck Sharp & Dohme B.V.

See pricing